Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma

被引：0
|
作者：
Leleu, Xavier
Touzeau, Cyrille
Benboubker, Lotfi
Facon, Thierry
Delain, Martine
Fourneau, Nele
Phelps, Charles
Forslund, Ann
Hellemans, Peter
Smit, Johan
Badamo-Dotzis, Julie
Moreau, Philippe
机构：
[1] Hop Claude Huriez, Serv Malad Sang, Lille, France
[2] CHU Nantes, Hop Hotel Dieu, Serv Hematol, F-44035 Nantes 01, France
[3] Hop Bretonneau, Ctr Hosp Univ Tours, Tours, France
[4] Janssen Res & Dev LLC, Beerse, Belgium
[5] Janssen Res & Dev LLC, Raritan, NJ USA
[6] Janssen Res & Dev, Div Janssen Cilag, Providing Serv, Issy Les Moulineaux, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8530
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
    Niesvizky, Ruben
    Wang, Luhua
    Orlowski, Robert Z.
    Bensinger, William
    Alsina, Melissa
    Gabrail, Nashat
    Gutierrez, Andres
    Kunkel, Lori
    Kauffman, Michael
    BLOOD, 2009, 114 (22) : 128 - 129
  • [32] BORTEZOMIB, LOW DOSE INTRAVENOUS MELPHALAN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Popat, R.
    Oakervee, H.
    Williams, C.
    Cook, M.
    Craddock, C.
    Basu, S.
    Singer, C.
    Odeh, L.
    Foot, N.
    Joel, S.
    Hallam, S.
    Harding, S.
    Mead, G.
    Cavenagh, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 365 - 366
  • [33] Bortezomib, low dose iv melphalan and dexamethasone for patients with relapsed multiple myeloma
    Popat, R.
    Williams, C.
    Cook, M.
    Craddock, C.
    Basu, S.
    Singer, C.
    Odeh, L.
    Foot, N.
    Joel, S.
    Hallam, S.
    Oakervee, H.
    Cavenagh, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 120 - 120
  • [34] Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
    Kropff, M
    Bisping, G
    Liebisch, P
    Sezer, O
    Einsele, H
    Straka, C
    Kroeger, N
    Metzner, B
    Engelhardt, M
    Lang, N
    Hentrich, M
    Wolf, H
    von Schilling, C
    Salwender, H
    Berdel, WE
    Kienast, J
    BLOOD, 2005, 106 (11) : 716A - 716A
  • [35] A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
    Monica Galli
    Silvia Salmoiraghi
    Joseé Golay
    Antonella Gozzini
    Claudia Crippa
    Norbert Pescosta
    Alessandro Rambaldi
    Annals of Hematology, 2010, 89 : 185 - 190
  • [36] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Richardson, PG
    Sonneveld, P
    Schuster, MW
    Irwin, D
    Stadtmauer, EA
    Facon, T
    Harousseau, JL
    Ben-Yehuda, D
    Lonial, S
    Goldschmidt, H
    Reece, D
    San-Miguel, JF
    Bladé, J
    Boccadoro, M
    Cavenagh, J
    Dalton, WS
    Boral, AL
    Esseltine, DL
    Porter, JB
    Schenkein, D
    Anderson, KC
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24): : 2487 - 2498
  • [37] A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
    Galli, Monica
    Salmoiraghi, Silvia
    Golay, Josee
    Gozzini, Antonella
    Crippa, Claudia
    Pescosta, Norbert
    Rambaldi, Alessandro
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 185 - 190
  • [38] PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
    Alsina, Melissa
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael S.
    Mukhopadhyay, Sutapa
    Paley, Carole S.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/ Refractory Multiple Myeloma
    Chari, Ajai
    Htut, Myo
    Zonder, Jeffrey A.
    Fay, Joseph W.
    Jakubowiak, Andrzej J.
    Levy, Joan B.
    Lau, Kenneth
    Burt, Steven M.
    Tunquist, Brian J.
    Hilder, Brandi W.
    Rush, Selena A.
    Walker, Duncan H.
    Ptaszynski, Mieke
    Kaufman, Jonathan L.
    CANCER, 2016, 122 (21) : 3327 - 3335
  • [40] A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma
    Takamatsu, Yasushi
    Sunami, Kazutaka
    Hata, Hiroyuki
    Nagafuji, Koji
    Choi, Ilseung
    Higuchi, Masakazu
    Uozumi, Kimiharu
    Masaki, Yasufumi
    Tamura, Kazuo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 503 - 509
12345